Barclays Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $169
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Overweight rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $150 to $169.
May 02, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays analyst Carter Gould has maintained an Overweight rating on Neurocrine Biosciences and increased the price target from $150 to $169.
The upgrade in the price target by Barclays reflects a positive outlook on Neurocrine Biosciences, likely due to strong company fundamentals or market position. This analyst endorsement can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100